Hutchmed/$HCM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Hutchmed
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
- Ticker
- $HCM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,790
- Headquarters
- Hong Kong, Hong Kong
- Website
- www.hutch-med.com
Hutchmed Metrics
BasicAdvanced
$2.6B
746.90
$0.02
0.45
-
Price and volume
Market cap
$2.6B
Beta
0.45
52-week high
$16.33
52-week low
$9.77
Average daily volume
52K
Financial strength
Current ratio
5.644
Quick ratio
5.453
Long term debt to equity
0.057
Total debt to equity
0.074
Interest coverage (TTM)
-12.14%
Profitability
EBITDA (TTM)
-20.515
Gross margin (TTM)
13.31%
Net profit margin (TTM)
3.26%
Operating margin (TTM)
-6.33%
Effective tax rate (TTM)
8.25%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-1.24%
Return on equity (TTM)
1.46%
Valuation
Price to earnings (TTM)
746.904
Price to revenue (TTM)
23.69
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
1,307.552
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.012
Growth
Revenue change (TTM)
-8.81%
Earnings per share change (TTM)
-96.19%
3-year revenue growth (CAGR)
-10.16%
10-year revenue growth (CAGR)
10.61%
3-year earnings per share growth (CAGR)
-23.52%
10-year earnings per share growth (CAGR)
3.28%
What the Analysts think about Hutchmed
Analyst ratings (Buy, Hold, Sell) for Hutchmed stock.
Analyst projections of the future price of Hutchmed stock.
Bulls say / Bears say
H1 oncology product revenue grew 23% to $121.4 million, with China sales of ELUNATE and SULANDA up 41% and 45%, respectively, while ex-US FRUZAQLA sales rose about 70%. Growth across China and overseas markets gives the commercial business more than one source of momentum. (SEC)
In the SAFFRON Phase III trial, ORPATHYS plus TAGRISSO cut the risk of disease progression or death by 45% and the risk of death by 32% versus chemotherapy. Regulatory applications are now under review in Europe and Japan, following a US submission. (Morningstar, Business Insider)
GSK's licence for HMPL-A830 has closed, bringing HUTCHMED a $110 million upfront payment and the chance of further milestone payments and royalties. GSK will handle later-stage development and commercialisation outside China, giving HUTCHMED a partner to advance the candidate globally. (SEC, Reuters)
Total H1 revenue was flat at $278.3 million, as Other Ventures revenue fell 14% while the oncology business grew. This leaves overall growth reliant on continued expansion in the core oncology segment. (SEC)
HUTCHMED reported $15.9 million of H1 net income on $278.3 million of revenue, while R&D and selling and administrative expenses both increased year on year. That leaves a relatively thin earnings base exposed to rising development and commercial costs. (SEC)
AstraZeneca, rather than HUTCHMED, commercialises ORPATHYS, so HUTCHMED relies on its partner to turn positive global trial results into overseas sales. That limits HUTCHMED's direct control over launch execution. (Morningstar)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Hutchmed Financial Performance
Revenues and expenses
Hutchmed Earnings Performance
Company profitability
Upcoming events
No upcoming events
Hutchmed News
AllArticlesVideos
Funds containing Hutchmed
Fund name | Fund size | $HCM weighting |
|---|---|---|
SPDR MSCI Emerging Markets Small Cap£EMSM | $647M | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.